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The NLRP3 inflammasome is activated in age-related
macular degeneration (AMD), but it remains unknown
whether its activation contributes to AMD pathol-
ogies. VEGF-A is increased in neovascular (‘‘wet’’)
AMD, but it is not known whether it plays a role in
inflammasome activation, whether an increase of
VEGF-A by itself is sufficient to cause neovascular
AMD and whether it can contribute to nonexudative
(‘‘dry’’) AMD that often co-occurs with the neovascu-
lar form. Here, it is shown that an increase in VEGF-A
results in NLRP3 inflammasome activation and is
sufficient to cause both forms of AMD pathologies.
Targeting NLRP3 or the inflammasome effector cyto-
kine IL-1b inhibits but does not prevent VEGF-A-
induced AMD pathologies, whereas targeting IL-18
promotes AMD. Thus, increased VEGF-A provides a
unifying pathomechanism for both forms of AMD;
combining therapeutic inhibition of both VEGF-A
and IL-1b or the NLRP3 inflammasome is therefore
likely to suppress both forms of AMD.
INTRODUCTION
Age-related macular degeneration (AMD) is the most common
cause of irreversible blindness in the elderly (Friedman et al.,
2004; van Leeuwen et al., 2003). AMDmanifests with the cardinal
features of progressive atrophic degeneration of the retinal
pigment epithelium (RPE) with sub-RPE deposits that affect
metabolic exchanges between the RPE and choroidal vessels
in nonexudative (‘‘dry’’) AMD or with choroidal neovasculariza-
tion (CNV) in neovascular (‘‘wet’’) AMD (Bird et al., 1995; Kliffen
et al., 1997). Importantly, patients with nonexudative AMD can
progress to develop neovascular AMD, and both forms of AMD
can occur simultaneously, suggesting a common pathomechan-
ism that is currently unknown, in part due to the lack of a mouse
model with features of both forms of AMD (Sunness et al., 1999).
Increased VEGF-A levels have been observed in neovascular
AMD, but it remains to be shown whether an increase in
VEGF-A alone is sufficient to cause neovascular AMD andCelthrough which pathomechanisms it may promote the disease
process (Funk et al., 2009). Increased hypoxia and oxidative
damage to the RPE have been regarded as critical factors in
AMD pathogenesis, which induce VEGF-A expression in the
RPE (Klettner and Roider, 2009). Consistent with the observed
increased VEGF-A levels in neovascular AMD, anti-VEGF-A
treatments have shown significant clinical benefit in patients
with neovascular AMD (Martin et al., 2011). In contrast, nonexu-
dative AMD is more common than neovascular AMD and causes
loss of vision in millions of individuals, but no established treat-
ments exist for nonexudative AMD. Thus, identifying a common
pathogenetic step for both forms of AMD would provide the op-
portunity for a targeted broad therapeutic approach for neovas-
cular and nonexudative AMD.
Genetic association data have provided evidence for linkage
of both forms of advanced AMD with the VEGF-A gene locus
(Fritsche et al., 2013; Yu et al., 2011), suggesting that increased
VEGF-A levels may promote not only neovascular AMD but also
nonexudative AMD. Thus, both forms of AMD may arise as
distinct manifestations of a common underlying process of
VEGF-A dysregulation.
Recently, NLRP3 inflammasome activation has been reported
in both nonexudative and neovascular AMD, but it is not known
whether VEGF-A promotes its activation (Kaneko et al., 2011;
Tarallo et al., 2012; Tseng et al., 2013). Activation of the
NLRP3 inflammasome results in autocatalytic cleavage of
caspase-1 precursor (with the generation of the active p10 and
p20 subunits), which leads to proteolytic activation of the potent
proinflammatory cytokines IL-1b and IL-18 (Latz et al., 2013).
Importantly, inflammasome activation has been suggested to in-
fluence various metabolic and aging diseases, including athero-
sclerosis, diabetes, gout, or obesity (Wen et al., 2012). However,
it is not known whether NLRP3 inflammasome activation has a
pathogenic role in the development of AMD, due to the lack of
a mouse model that manifests chorioretinal pathologies as
seen in both forms of AMD with progressive age, in which the
role of the inflammasome could be tested. Recent studies
have proposed either an inhibitory or a promoting role of the
NLRP3 inflammasome for AMD (Doyle et al., 2012; Tarallo
et al., 2012). Inhibition of the NLRP3 inflammasome prevented
RPE degeneration, induced by DICER1 loss or Alu RNA expo-
sure, whereas it increased neovascular lesions in an acute laser
wound-healing model (Doyle et al., 2012; Tarallo et al., 2012).l Reports 4, 945–958, September 12, 2013 ª2013 The Authors 945
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Figure 1. Increased VEGF-A Levels Result in a Progressive RPE Barrier Breakdown
(A) The RPE is themain cell type of VEGF-A expression in the adult eye. Immunolabeling of an adult posterior eye of a VEGF-Ahyper mouse (15months old) for b-gal
reflects cellular expression of VEGF-A (green). Strong VEGF-A expression is observed in RPE cells (arrow), whereas low-level VEGF-A expression is seen in retinal
cells of the ganglion cell layer (GCL) and inner nuclear layer (INL) (arrowheads), but not the photoreceptor layer (ONL). Scale bar, 50 mm.
(B) VEGF-A ELISA of RPE/choroid and retinal tissue in adult VEGF-Ahyper mice (KI) and control littermate (WT) mice (n = 7/group) shows a significant increase of
VEGF-A levels in the RPE/choroid tissues in VEGF-Ahyper mice. Serum levels of VEGF-A are elevated in mutant mice independently of age as well (n = 3/group).
Error bars, mean ± SD. *p < 0.05.
(C) Mouse and human RPE cells express the VEGF-A receptors Flt1 and Flk1 and all major VEGF-A isoforms, particularly VEGF-A164 and VEGF-A120 (VEGF-A165
and VEGF-A121 in human).
(D) Focal RPE barrier breakdown is observed in VEGF-Ahyper micewith cytoplasmic and nuclear accumulation of b-catenin. Colabelingwith Alexa 488-conjugated
phalloidin (green) shows that in normal RPE cells, phalloidin and b-catenin (red) labeling is strongest along cell membranes, whereas in RPE cells with RPE barrier
breakdown, b-catenin labeling along the cell membranes is attenuated and increased in the nuclei or cytoplasm. A 7-month-old VEGF-Ahyper mouse is shown.
Scale bar, 20 mm.
(E) Colabeling of cell junction proteins b-catenin (red) and ZO-1 (green) shows loss of membrane-bound ZO-1 and b-catenin with nuclear and cytoplasmic
accumulation. A 7-month-old VEGF-Ahyper mouse is shown. Scale bar, 50 mm.
(legend continued on next page)
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However, these studies were limited by the use of experimental
models that do not reflect the age-dependent progressive
chorioretinal pathologies seen in AMD, such as the acute laser
injury model in which neovascularization occurs in the setting
of healthy RPE cells, which is in fact an acute wound-healing
model and only a very limited model for neovascular AMD (He
andMarneros, 2013). Thus, the role of the NLRP3 inflammasome
in such an acute wound-healing model is likely to differ from its
role in human AMD or in a mouse model that develops cardinal
features of AMD in a progressive age-dependent manner
accompanied by degenerative RPE changes.
Here, mice with increased VEGF-A levels are shown to
develop age-dependent progressive cardinal features of both
nonexudative and neovascular AMD, in which NLRP3 inflamma-
some activation occurs as seen in human AMD. Targeting
NLRP3 or the inflammasome effector cytokine IL-1b reduces
VEGF-A-induced chorioretinal pathologies in these mice, such
as RPE barrier breakdown and CNV lesions, whereas IL-18 defi-
ciency promotes CNV lesions. The data provide a unifying path-
omechanism for both forms of AMD and show that what has
been considered as a multifactorial pathogenesis can be trig-
gered by an increase of a single growth factor, VEGF-A, which
induces NLRP3 inflammasome activation to promote AMD-like
pathologies.
RESULTS
Age-Dependent RPE Barrier Breakdown in Mice with
Increased VEGF-A Levels
To determine whether an increase in VEGF-A by itself is sufficient
to cause eye pathologies as seen in AMD, mutant mice were
analyzed that have increased VEGF-A protein levels. The in-
crease of VEGF-A levels occurs in adult heterozygote VEGF-
AlacZKI/WT mice (hereafter described as VEGF-Ahyper mice) as a
consequence of the insertion of an IRES-NLS-lacZ-SV40pA
sequence into the 30 UTR of the VEGF-A gene locus
at +202 bp 30 to the stop codon (Cervi et al., 2007; Miquerol
et al., 1999), which removes miRNA binding sites in the 30 UTR
that would inhibit VEGF-A mRNA translation (Jafarifar et al.,
2011). Adult transgenic mice that express lacZ driven by a pro-
moter that is active in RPE cells (Dct-lacZ-SV40pA mice) (Wilkie
et al., 2002) showed no eye abnormalities, suggesting that
changes observed in the eyes of VEGF-Ahyper mice are due to(F) FITC-dextran flux assays with RPE cells demonstrate that VEGF-A165 treatmen
dextran (n = 3). Error bars, mean ± SD. *p < 0.05. y axis indicates fluorescence a
(G and H) Choroidal flat mount staining of eyes from VEGF-Ahyper mice with b-cate
young VEGF-Ahyper eyes (2months old; G) but that these areas expand and becom
the mice (12 months old; H). Scale bars, 200 mm.
(I) Magnification of area from (H) that delineates normal-appearing RPE (arrow
(arrowhead). Scale bar, 200 mm.
(J) Adult VEGF-Ahypo mice, hypomorphic for VEGF-A, express b-gal (green) fr
bar, 100 mm.
(K) In contrast, adult VEGF-Ahyper mice, with increased VEGF-A levels, show the
VEGF-Ahypo mice but show multifocal RPE barrier breakdown. Scale bar, 100 mm
(L) Mice that express VMD2-Cre specifically in RPE cells (white nuclear staining fo
these mice, Cre+ RPE cells are expected to have lower levels of VEGF-A than C
patches, therefore expressing higher levels of VEGF-A. Scale bar, 100 mm.
See also Figure S1.
Celincreased VEGF-A levels, and not due to the insertion of the
lacZ sequence and b-galactosidase (b-gal) expression in RPE
cells. In additional control experiments, mice were examined in
which the IRES-NLS-lacZ-SV40pA sequence was inserted
immediately after the VEGF-A stop codon, resulting in a hypo-
morphic VEGF-A allele (VEGF-Ahypo mice) while maintaining
b-gal expression from the endogenous VEGF-A locus (Damert
et al., 2002). These VEGF-Ahypo mice showed b-gal expression
in ocular tissues like VEGF-Ahyper mice, but without ocular
pathologies, further demonstrating that the observed eye
changes in VEGF-Ahyper mice are due to the increased VEGF-A
levels (Figures 1J and 1K).
In these VEGF-Ahyper mice, nuclear b-gal expression (due to
the nuclear localization signal between the IRES sequence and
the lacZ) reflects accurately VEGF-A expression at single-cell
resolution (Figures 1A, S1A, and S1B). The use of an IRES
sequence allows independent translation of both VEGF-A and
the lacZ reporter from the same bicistronic mRNA produced by
the targeted allele. Choroid/RPE tissues as well as retinas from
adult VEGF-Ahyper mice showed significantly increased VEGF-A
protein levels compared to control littermate mice, albeit retinas
having lower VEGF-A levels (Figure 1B). Consistent with this
observation, staining for b-gal showed that RPE cells are the
main cell type in the choroid and retina to express VEGF-A and
that strong VEGF-A expression in the RPE is maintained at all
ages (up to 24-month-old mice were studied) (Figure 1A). Simi-
larly, VEGF-A serum levels were increased in VEGF-Ahyper
mice, and this increase was maintained with progressive age
(Figure 1B). A cell line derived from human RPE cells, ARPE-19
cells, and freshly isolated primary mouse RPE cells express
the VEGF-A receptors Flt1 and Flk1, and all major VEGF-A
isoforms, most prominently VEGF-A164 and VEGF-A120 (VEGF-
A165 and VEGF-A121 in human) (Figure 1C). VEGF-A treatment
of ARPE-19 cells induced phosphorylation of VEGFR2 and its
downstream target AKT, which could be blocked by a specific
VEGFR2 kinase inhibitor (Figure S1C), demonstrating that
VEGF-A can elicit VEGFR2-dependent VEGF-A pathway activa-
tion in RPE cells.
VEGF-A pathway activation can lead to RPE barrier break-
down of RPE monolayers in vitro (Ablonczy et al., 2011). To
test whether increased VEGF-A levels in VEGF-Ahyper mice
are associated with RPE barrier disruption, choroidal flat
mounts from these mice were stained for b-catenin and zonulat induces barrier breakdown and increased transepithelial flux of 10 kDa FITC-
rbitrary units (AU).
nin (red) shows that RPE barrier breakdown is observed in small foci (arrow) in
e confluent and affect most of the posterior eye (arrows)with progressive age of
) with its honeycomb pattern from lesional abnormal-appearing RPE cells
om the endogenous VEGF-A gene locus but show normal RPE cells. Scale
same expression of b-gal (green) from the endogenous VEGF-A gene locus as
.
r Cre) that are heterozygous for VEGF-Afl/fl and carry the VEGF-Ahyper allele; in
re RPE cells. RPE barrier breakdown occurs predominantly within Cre RPE
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Figure 2. Progressive Age-Dependent Degeneration of the RPE and
Photoreceptors in Mice with Increased VEGF-A Levels
(A–D) Although the retina and choroid/RPE appear unremarkable in young
adult VEGF-Ahyper mice (6 weeks old; B), with progressive age, a severe RPE
atrophy is noticed with loss of pigment granules, thinning of RPE cells, and
massive sub-RPE deposit accumulation (black arrow in D). The photoreceptor
nuclear layer (ONL) is severely attenuated (white double arrow in D) compared
to age-matched littermate control retinas (C). In addition, photoreceptor inner
and outer segments (black double arrow) are significantly shortened (D). Scale
bars, 20 mm. The asterisks (*) indicate Bruch’s membrane.
(E) Quantification of RPE and photoreceptor length reveals significantly thin-
ned RPE and attenuated photoreceptor outer and inner segments (OS and IS,
respectively) and ONL in aged mutant mice (20 months of age). n = 5/group.
Error bars, mean ± SD. *p < 0.05.
(F) Photoreceptor degeneration is reflected in reduced rhodopsin protein
levels in posterior eyes of aged VEGF-Ahyper mice (KI, 12 and 17 months old)
948 Cell Reports 4, 945–958, September 12, 2013 ª2013 The Authoroccludens-1 (ZO-1). In RPE cells of young VEGF-Ahyper mice and
in healthy control mice, immunolabeling for b-catenin and ZO-1
shows a membrane-bound localization, as b-catenin is part of
the adherens junctions, and ZO-1 is part of the tight junctions,
both comprising the RPE barrier. In adult VEGF-Ahyper mice,
focal RPE cytoskeletal abnormalities were observed with loss
of the typical RPE honeycomb cell morphology, and these
changes were associated with loss of membrane-bound ZO-1
and b-catenin and their increased cytoplasmic and nuclear
accumulation, providing a morphologic correlate to RPE barrier
breakdown (Figures 1D and 1E). These changes were observed
in all VEGF-Ahyper mice examined, whereas they were not seen in
any control littermate mice (>200 mutant and control mice were
examined between the ages of 4 weeks and 24 months of age).
Although young VEGF-Ahyper mice showed multiple small foci
of RPE barrier breakdown and morphological abnormalities of
the RPE (Figure 1G), aged mice (>7 months old) showed large
confluent areas of these defects, mostly in the central part of
the posterior eye (Figures 1H and 1I). Thus, a chronic increase
of VEGF-A levels is sufficient to cause an age-dependent pro-
gressive RPE barrier breakdown in vivo. Furthermore, VEGF-A
treatment of human RPE monolayers resulted in a rapid break-
down of barrier function in FITC-dextran flux assays (Figure 1F),
suggesting that the observed RPE barrier breakdown in VEGF-
Ahyper mice is a direct consequence of increased VEGF-A levels.
To provide further evidence for a direct role of VEGF-A for RPE
barrier breakdown in vivo, mice were generated that become
heterozygous for VEGF-A postnatally, specifically in patches of
the RPE, and carry the VEGF-Ahyper allele (VMD2-Cre+VEGF-
Afl/WTVEGF-Ahyper mice). In thesemice, foci of RPE barrier break-
down were observed primarily at areas of the RPE with absence
of Cre expression (and thus increased VEGF-A levels), and not
in Cre-positive RPE patches (with normalized VEGF-A levels)
(Figure 1L).
Increased VEGF-A Levels Are Associated with Cardinal
Features of Nonexudative AMD
Eyes from VEGF-Ahyper mice and control mice were examined up
to 24 months of age, revealing an age-dependent progressive
RPE atrophy and degenerative changes with loss of RPE
pigment granules in mutant mice (Figures 2D, S2C, and S2G).compared to control littermate mice (WT). Normalized densitometric values
are indicated.
(G and H) Electron microscopy demonstrates massive accumulation of basal
laminar sub-RPE deposits in aged (20 months old; H) VEGF-Ahyper mice
compared to age-matched control littermate mice (G). The RPE is thinned in
VEGF-Ahyper mice (black double arrow), sub-RPE deposits (white double
arrow) consist of electron-dense deposits resembling basal laminar deposits,
and electron-lucent spaces indicate lipid-like material that was removed
during fixation (black arrows). BrM, Bruch’s membrane. OS, photoreceptor
outer segments. Scale bars, 500 nm.
(I) Oil redO staining in an aged VEGF-Ahyper mouse shows accumulation of lipid
droplets in sub-RPE deposits (white arrow). Black arrowhead points to Bruch’s
membrane. CL, choroidal layer. Scale bar, 10 mm.
(J) RPE cell degeneration in aged VEGF-Ahyper mice (15 months old) with RPE
cells focally undergoing cell death, demonstrated by cleaved caspase-3
(Asp175) immunostaining (white arrows). Scale bar, 50 mm.
See also Figure S2.
s
Although young mutant mice have a normal morphological
appearance of most of the RPE and retina (Figure 2B), older
mice showed progressive degeneration of the RPE, with some
RPE cells undergoing cell death with positive staining for cleaved
caspase-3 (Asp175) (Figure 2J). The RPE defects were associ-
ated with severe progressive age-dependent degeneration of
the photoreceptors, with shortening of the photoreceptor outer
and inner segments and a significant attenuation of the photore-
ceptor nuclear cell layer (outer nuclear layer [ONL]) (Figures 2D,
2E, S2G, and S2H). Apoptotic nuclei of photoreceptors were also
observed, and rhodopsin levels were significantly reduced in
retinas of aged VEGF-Ahyper mice (Figures 2F, S2G, and S3G),
reflecting photoreceptor degeneration. Electron microscopy re-
vealed massive age-dependent electron-dense sub-RPE depo-
sit formation (Figures 2H, S2B, and S2E), strongly resembling
basal laminar deposits in AMD. Droplet-like electron-lucent
spaces within these deposits (Figures 2H, S2C, and S2D)
indicate lipid accumulation removed during fixation, as has
been reported in basal laminar deposits in human AMD
(Curcio et al., 2005b), further supported by oil red O-positive
sub-RPE accumulations (Figure 2I). Furthermore, ‘‘wide-spaced
collagen’’-like material could be seen in these sub-RPE deposits
(Figure S2B), a typical finding in human AMD. These deposits
were not observed in young VEGF-Ahyper mice, whereas sub-
RPE deposits increased progressively with age. Vacuolar degen-
eration of RPE cells (Figures S2E and S2F), also found in human
eyes with early AMD (Anderson et al., 2002), was an early sign of
RPE damage and could already be seen focally in the eyes of
young VEGF-Ahyper mice, before the onset of photoreceptor
loss (Figures 5A and S3C). In addition, round phalloidin-negative
autofluorescent droplet-like sub-RPE deposits accumulated
with progressive age particularly at sites where RPE cells had
lost their normal honeycomb pattern morphology (Figures S2I,
S2J, and 4D–4G; these deposits where also negative for F4/80
as seen in Figure S3E).
Thus, a chronic increase of VEGF-A levels leads to early
degenerative changes in the RPE and progressive basal
laminar sub-RPE deposit formation with subsequent degenera-
tion of photoreceptors. Choroidal vessels maintained endothelial
fenestrations, and perfusion experiments with fluorescein-
labeled lectins did not show a significant abnormality in
choroidal perfusion, suggesting that the RPE degeneration is
not a consequence of a choroidal vascular perfusion defect
(Figure 3A).
Progressive CNV as in Neovascular AMD in VEGF-Ahyper
Mice
Disruption of the RPE barrier would be expected to lead to
degeneration of photoreceptors and accumulation of a subreti-
nal inflammatory cell infiltrate. Indeed, at sites of RPE barrier
breakdown, increased photoreceptor apoptosis was seen in
VEGF-Ahyper mice (Figure S3G), as well as a subretinal myeloid
cell inflammatory infiltrate (Figures S3E and S3H).
It has been hypothesized that RPE barrier breakdown and a
proangiogenic myeloid cell inflammatory infiltrate promote
CNV in neovascular AMD, although direct evidence for this hy-
pothesis is missing. Eyes from VEGF-Ahyper mice showed focal
early vacuolar degeneration of RPE cells already at 4–6 weeksCelof age, whereas overlying photoreceptors were intact (Figures
5A and S3C). The first-observed changes in the retina overlying
RPE defects showed migration of retinal Muller glia cells toward
sites of RPE degeneration (Figure 5A), which dramatically accu-
mulated with progressive age at sites of RPE defects and re-
placed photoreceptors (Figure 5B). Subsequently, progressive
formation of CNV lesions was observed at sites of increased
RPE degeneration, starting in young mice and progressing to
large confluent multifocal CNV lesions in aged mice (Figures
3A–3D and S3I –S3K). The proliferating new vessels in CNV
lesions were perfused through the choroidal vasculature (Figures
3A and 3B). RPE cells overlying CNV lesions showed increased
RPE barrier breakdown with cytoplasmic b-catenin accumula-
tion (Figures 3F, S3K, and S3L) and degenerative atrophic
changes (Figures S3A and S3B), linking RPE barrier breakdown
with CNV formation.
CNV lesions in VEGF-Ahyper mice showed striking resem-
blance to neovascular AMD lesions in humans with the formation
of neovascular membranes and loss of the overlying photore-
ceptors (Figures 3C–3E). Although the photoreceptor layer was
attenuated throughout the retina with increasing age associated
with RPE degenerative changes, a cardinal feature of nonexuda-
tive AMD, a complete loss of the photoreceptor layer was limited
to the retina overlying CNV lesions (Figures 3D and 5B), as is typi-
cally seen in neovascular AMD. At sites of CNV lesion formation,
retinal Muller glia cells completely replaced photoreceptors with
progressive age (Figure 5B). Thus, VEGF-Ahyper mice develop
cardinal features of both nonexudative and neovascular AMD
with progressive age.
NLRP3 Inflammasome Activation in Mice with Increased
VEGF-A Levels
To identify molecular mechanisms that promote the AMD-like
pathologies in aged VEGF-Ahyper mice, RPE cells were isolated
from eyes of aged VEGF-Ahyper mice and control littermate
mice for gene expression-profiling experiments. Among the
highly upregulated genes in the RPE of VEGF-Ahyper mice were
the inflammasome component NLRP3, IL-1b, and the comple-
ment cascade component C1q (Table S1). It has recently been
reported that the NLRP3 inflammasome is activated in AMD,
but the significance of NLRP3 inflammasome activation for the
pathogenesis of AMD is not known and has not been validated
in an animal model that reflects the human disease process
(Kaneko et al., 2011; Tarallo et al., 2012; Doyle et al., 2012).
The complement pathway component C1q, found in drusen in
AMD, has been shown to activate the NLRP3 inflammasome in
peripheral blood mononuclear cells in vitro, but whether
NLRP3 inflammasome activation in macrophages plays a path-
ogenic role for AMD has not been shown (Doyle et al., 2012).
Fatty acids have also been shown to be able to activate the
NLRP3 inflammasome, and these lipids are also found in drusen
and basal laminar deposits in AMD (Curcio et al., 2005a; Duewell
et al., 2010; Wen et al., 2011). Similarly, the basal laminar sub-
RPE deposits in aged VEGF-Ahyper mice showed evidence for
lipid deposition by electron microscopy and oil red O staining
(which binds triglycerides, esterified cholesterols, and fatty
acids) (Figure 2I), which may promote inflammasome activation
in the RPE of these mice.l Reports 4, 945–958, September 12, 2013 ª2013 The Authors 949
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Figure 3. CNV and NLRP3 Expression in Aged VEGF-Ahyper Mice
(A and B) Perfusion experiments in aged white VEGF-Ahyper mice with fluorescein-conjugated tomato lectin and subsequent whole-mount staining for CD31 and
phalloidin show that proliferating neovessels (CD31, red) originate from the underlying perfused choroidal vasculature (green) and extend into the sub-RPE space.
Autofluorescent round deposits can be seen at sites of CNV lesions. Scale bars, 50 mm. Inset in (B) represents modeled z-stack of lesion.
(C) Representative section of CNV lesion in aged VEGF-Ahyper mice shows massive subretinal neovascularization (arrow). Scale bar, 20 mm.
(D) Representative image of a fully formed CNV lesion in a 7-month-old VEGF-Ahyper mouse that resembles a neovascular membrane in neovascular AMD (arrow).
Neovascularization and fibrosis have completely replaced the photoreceptor layer at the site of CNV formation. Scale bar, 50 mm.
(E) In age-matched control littermate mice, such lesions were not seen. Scale bar, 50 mm.
(F) Colocalization of RPE barrier breakdown with CNV lesions. Choroidal flat mount of a 24-month-old white VEGF-Ahyper mouse in which choroidal perfusion is
assessed by intracardiac administration of a fluorescein-conjugated tomato lectin (green). Subsequent whole-mount staining for CD31 (red) highlights prolif-
erating neovessels from underlying perfused choroidal vessels (green), and labeling for b-catenin (white) shows RPE barrier breakdown at sites of neo-
vascularization with cytoplasmic accumulation of b-catenin. Scale bar, 50 mm.
(legend continued on next page)
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Immunostaining showed strong NLRP3 expression in RPE
cells predominantly within CNV lesions in VEGF-Ahyper mice (Fig-
ures 3G and S4A), linking increased RPE barrier breakdown and
RPE degeneration with NLRP3 inflammasome activation and
subsequent neovascularization. In addition, strong accumula-
tion of C1qwas observed in a perivascular pattern in CNV lesions
(Figures 3H and 3I), consistent with the gene expression-profiling
results and its reported role as an NLRP3 inflammasome
activator.
In ARPE-19 cells, oxidative stress can activate the NLRP3
inflammasome (Kauppinen et al., 2012). Notably, VEGF-A has
been shown to induce oxidative stress in endothelial cells,
whereas challenging RPE cells in vitro with oxidants increased
VEGF-A levels (Klettner and Roider, 2009; Monaghan-Benson
and Burridge, 2009). Consistent with these observations,
VEGF-A treatment resulted in a rapid and significant increase
of oxidative stress (determined by measuring superoxide reac-
tion with dihydroethidium) in ARPE-19 cells (Figure 3K), and
staining for acrolein (a marker for oxidative damage-induced
lipid peroxidation) (Dorrell et al., 2009) was increased focally in
RPE cells of aged VEGF-Ahyper mice (Figure 3J), suggesting
that a chronic increase of VEGF-A results in increased oxidative
damage in RPE cells.
Mice with deficiency of the antioxidant enzyme SOD1, result-
ing in increased superoxide levels, develop with progressive age
RPE barrier breakdown and some AMD-like pathologies, albeit
much more delayed and less striking than VEGF-Ahyper mice
(Imamura et al., 2006). Because oxidative stress results in an in-
crease in VEGF-A levels in RPE cells in vitro, and SOD1 null mice
phenocopy to some degree VEGF-Ahyper mice, it is possible that
the observed AMD-like pathologies in SOD1 null mice may be
mediated in part by increased VEGF-A levels. Indeed, VEGF-A
serum levels in young SOD1 null mice, prior to the manifestation
of AMD-like pathologies, were increased compared to control
littermate mice (Figure 3L), further suggesting that increased
VEGF-A levels are central to the development of AMD-like
pathologies. Oxidative stress induced by SOD1 knockdown in
ARPE-19 cells (as well as in a lens epithelial cell line) resulted
in increased IL-1b levels in the cell culture supernatant (Fig-
ure 3M), demonstrating a contributory role of oxidative stress
to inflammasome activation in RPE cells as well.(G) Strongly increased NLRP3 expression in the RPE/choroid (arrow) with attenua
mouse. Scale bar, 50 mm.
(H) Perivascular accumulation of C1qA within CNV lesions (arrow). A 15-month-o
(I) Western blotting demonstrates accumulation of C1qA in choroid/RPE tissues
mulation of C1qA. Choroid/RPE or retinal tissues represent pools from three 25-m
values are indicated.
(J) Acrolein, a marker for ROS-induced lipid peroxidation, is increased focally in
DAPI nuclear staining was performed; photoreceptor outer segments show auto
(K) VEGF-A165 treatment of ARPE-19 cells loaded with 10 mM dihydroethidium (
FACS (PerCP-Cy5.5 channel). y Axis shows mean fluorescence intensity (MFI) of
the shift of fluorescence induced by VEGF-A165, representing increased superox
(L) VEGF-A serum levels are increased in young (7 weeks old) SOD1/ mice com
mean ± SD. *p < 0.05.
(M) SOD1 is efficiently depleted using SOD1-targeted siRNA, demonstrated by w
with 4 ng/ml IL-1a, shows that SOD1 knockdown increases levels of the inflamma
cells (n = 4/group). Error bars, mean ± SD. *p < 0.05.
See also Figure S3.
CelThus, degenerative RPE changes following VEGF-A-induced
RPE barrier breakdown in VEGF-Ahyper mice are associated
with increased sub-RPE lipid and complement C1q deposits
and increased oxidative damage, all factors promoting inflam-
masome activation. To test whether in VEGF-Ahyper mice
NLRP3 inflammasome activation occurs, the protein levels of
the active caspase-1 subunits p10 and p20 were examined,
which are derived from caspase-1 precursor through autocata-
lytic cleavage when the inflammasome is activated. Western
blotting confirmed activation of the inflammasome with
increased p10 and p20 active subunits in RPE/choroid tissues
of aged VEGF-Ahyper mice, whereas control littermate mice
showed no inflammasome activation (Figure 4A). Furthermore,
immunostaining showed coexpression of NLRP3 and p10 focally
in the RPE/choroid of aged VEGF-Ahyper mice, consistent with
NLRP3 inflammasome activation (Figures 4B, S4B, and S4C).
Choroidal flat mounts from aged VEGF-Ahyper mice showed
that increased NLRP3 expression was limited to degenerative
RPE cells that had lost their typical honeycomb appearance,
whereas no NLRP3 expression was seen in normal-appearing
adjacent RPE cells or macrophages (Figures 4C and S4D).
Notably, NLRP3 expression and degenerative changes of RPE
cells were often seen in association with a large number of round
extracellular autofluorescent deposits that were phalloidin nega-
tive (average diameter, 25.6 ± 6.8 mm; average area, 574.8 ±
190.8 mm) (Figures 4D–4G).
Targeting the NLRP3 Inflammasome Inhibits AMD-like
Pathologies in VEGF-Ahyper Mice
To test whether NLRP3 inflammasome activation in VEGF-Ahyper
mice contributes to VEGF-A-induced AMD pathologies, NLRP3
or the inflammasome effector cytokines IL-1b and IL-18 were
targeted genetically in VEGF-Ahyper mice. NLRP3, IL-1 receptor
type 1, and IL-18 null mice showed no AMD-like pathologies.
Notably, targeting NLRP3, IL-1 receptor type 1 (abolishing
IL-1b signaling), or IL-18 in VEGF-Ahyper mice did not prevent
the observed chorioretinal pathologies, and double-mutant
mice showed RPE barrier breakdown, RPE degeneration, and
multifocal CNV lesions with macrophage infiltration as seen in
VEGF-Ahyper mice (Figures 4H and S4E–S4G). However, defi-
ciency of NLRP3 or IL-1 receptor type 1 in VEGF-Ahyper micetion or loss of the overlying photoreceptor layer in a 15-month-old VEGF-Ahyper
ld VEGF-Ahyper mouse is shown. Scale bar, 50 mm.
of aged VEGF-Ahyper mice, whereas control littermate mice showed no accu-
onth-old VEGF-Ahyper mice or control mice. Normalized relative densitometric
abnormal RPE cells in aged VEGF-Ahyper mice (green, arrow) (15 months old).
fluorescence (green). Scale bar, 50 mm.
DHE) induces increased oxidative stress (superoxide indicator), measured by
triplicate experiments (n = 3/group). A representative histogram demonstrates
ide species. Error bars, mean ± SD. *p < 0.05.
pared to age- and gender-matched control littermate mice (n = 5). Error bars,
estern blotting of ARPE-19 cell lysate. Cell culture supernatant of cells, primed
some effector cytokine IL-1b in both ARPE-19 cells and the B-3 lens epithelial
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Figure 4. Blockade of the NLRP3 Inflammasome Reduces CNV Lesions in VEGF-Ahyper Mice
(A) Left: western blotting of posterior eye lysates from 12- and 17-month-old VEGF-Ahyper mice (KI) and control littermate mice (WT) shows activation of the
inflammasomewith strong upregulation of the caspase-1 active subunit p20 inmutant mice. Right: pools of RPE/choroid or retinal tissue from three 25-month-old
VEGF-Ahyper mice (KI) and control littermate mice (WT) show strong upregulation of the p10 caspase-1 active subunit in the RPE/choroid, but not in the retina,
demonstrating inflammasome activation in RPE/choroid tissues of VEGF-Ahyper mice. Normalized densitometric values are indicated.
(B) NLRP3 (green, arrows) is strongly expressed in the RPE/choroid in VEGF-Ahyper mice (15 months old). Macrophages are stained with F4/80 (white). Colabeling
for the activated p10 subunit of caspase-1 (red) with NLRP3 (green) shows inflammasome activation. Scale bar, 50 mm.
(C) NLRP3 immunostaining of choroidal flat mounts with expression of NLRP3 in RPE cells that show abnormal cellular morphology (phalloidin [phall], white;
arrow), whereas normal-appearing RPE cells with typical honeycomb cytoarchitecture do not express NLRP3 (red) (13months old). No NLRP3 expression is seen
in F4/80+ macrophages (green, arrowhead). Scale bar, 50 mm.
(legend continued on next page)
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reduced the number of CNV lesions that formed in 6-week-old
mice, whereas deficiency in IL-18 resulted in a significantly
increased number of CNV lesions compared to double-mutant
VEGF-Ahyper mice lacking IL-1R1 or NLRP3 (Figure 4I). VEGF-A
protein levels in the RPE/choroid, retina, or serum were not
increased in IL-18 null mice compared to NLRP3 or IL-1R1 null
mice, suggesting that IL-18 deficiency promotes CNV lesion for-
mation through VEGF-A-independent mechanisms (data not
shown). Thus, NLRP3 inflammasome activation and the resulting
increase in active IL-1b, which acts as a potent proangiogenic
factor, promote VEGF-A-induced AMD pathologies, such as
RPE barrier breakdown and CNV lesion formation.
Macrophages Activate Proangiogenic Retinal Glia Cells
to Promote CNV
To determine which cell types are critical for promoting CNV, the
spatiotemporal cellular events that lead to CNV lesion formation
in VEGF-Ahyper mice were analyzed. Retinal Muller cell accumu-
lation and increased glial fibrillary acid protein (GFAP) expression
occur in human AMD retinas, but the significance of these Muller
cells for AMD pathogenesis is not known (Wu et al., 2003). Eyes
of VEGF-Ahyper mice showed a progressive increase of GFAP
expression in retinal cells overlying evolvingCNV lesions (Figures
5C–5F). In young mutant mice at sites of accumulation of a
myeloid cell infiltrate between the RPE and the retina, GFAP
expression in cells of the overlying retina was increased, and
Muller cells migrated toward the RPE prior to neovessel forma-
tion (Figure 5C). Strong GFAP staining and retinal Muller cell
accumulation were observed subsequently in evolved CNV
lesions (Figures 5D and 5E). Increased N-cadherin expression
was also observed in Muller cells at sites of evolving CNV
lesions, a marker for proliferating glia cells (Figure S5H). These
findings suggest that RPE barrier breakdown and macrophage
infiltration into the space between the retina and the RPE occur
first and that these macrophages subsequently activate retinal
Muller glia cells to promote CNV.
Although infiltrating macrophages in VEGF-Ahyper mice do not
stain for VEGF-A (b-gal), RPE cells in CNV lesions strongly ex-
pressed VEGF-A (Figures 5I and S3E). Overlying retinal glia cells
that infiltrated CNV lesions strongly expressed VEGF-A as well
(Figures 5H and 5I). Furthermore, these cells showed high
expression of the proangiogenic cytokine IL-1b and of IL-18,
and colabeling for GFAP confirmed that these cells were retinal
Muller glia cells (Figures 5G–5K and S5A–S5D). Choroidal flat
mounts, in which the retina was removed, showed glia Muller
cells adhering to the RPE and infiltrating CNV lesions and that
these cells were the main source of IL-1b in CNV lesions (Fig-
ure S5E). Glia cells infiltrated degenerative RPE cells particularly(D–G) Round autofluorescent extracellular deposits accumulate at sites of RPE de
phalloidin negative (E) and show autofluorescence with UV light (F), or the green li
these deposits. Scale bars, 50 mm.
(H) RPE barrier breakdown (b-catenin, red), macrophage infiltration (F4/80, w
despite genetic inactivation of IL-1R1, NLRP3, or IL-18 in these mice. Represen
Scale bars, 100 mm.
(I) Quantitative analysis of CNV lesion numbers per age-matched mutant mice (
choroidal flat mounts stained for b-catenin and CD31). No CNV lesions were seen
(n > 7 mice/group).
See also Figure S4.
Celat sites with high density of autofluorescent sub-RPE deposits
(Figures S5G and S5I).
The observations in CNV formation in VEGF-Ahyper mice sug-
gest that RPE defects and barrier breakdown are followed by a
macrophage infiltrate into the space between the retina and
the RPE that activates retinal Muller glia cells, which promote
CNV through secretion of proangiogenic factors including
VEGF-A and IL-1b. If this sequence of events is required for neo-
vascularization, ablation of themyeloid cell infiltrate should result
in reduced glia cell activation and inhibition of subsequent neo-
vascularization. This hypothesis was tested in a laser injury
model of CNV, in which disruption of the RPE barrier is achieved
through a laser that targets the pigmented RPE cells and leads to
subsequent CNV lesions through proliferation of blood vessels at
the site of laser injury. Although this acute injury model is limited
in the assessment of the role of chronic changes for AMD path-
ogenesis, it allows the characterization of acute spatiotemporal
events during neovascularization in the choroid (He and Mar-
neros, 2013). Similar to CNV lesion formation in VEGF-Ahyper
mice, time course experiments showed that in the laser injury
model of CNV, macrophages infiltrate the site of laser injury
early, followed by the formation of a NG2+SMA+ myofibroblastic
scaffold into which Muller glial cells infiltrate, before neovascula-
rization occurs (Figures 6A–6G). Like in CNV lesions in VEGF-
Ahyper mice, VEGF-A expression could not be detected in
macrophages in laser-inducedCNV lesions, but VEGF-A expres-
sion was seen in RPE cells as well as glia cells overlying CNV
lesions, which also expressed IL-1b (Figures S6A–S6D). Low-
level NLRP3 expression was observed only in a few RPE cells
in laser lesions, and not in lesional macrophages (Figures S6E
and S6F). NLRP3 protein levels in lysates from pooled choroids
of wild-type (WT) mice 3 days after laser injury were much lower
and almost undetectable when compared to choroid lysates
from age-matched unlasered VEGF-Ahyper mice (Figure S6G),
suggesting that VEGF-Ahyper mice are better suited to investigate
the role of the NLRP3 inflammasome for CNV than the laser
injury-wounding model.
Macrophage populations after wound injury undergo an
M2-like polarization with expression of the prototypic M2-
macrophage marker Arg1. Consistent with the CNV laser injury
model representing an acute wound-healingmodel of neovascu-
larization, immunolabeling for Arg1 and F4/80 confirmed that
most macrophages that accumulate at sites of laser injury
are Arg1+F4/80+ M2-like macrophages, whereas nonlesional
choroidal F4/80+ cells were Arg1 (Figure S6H). In human
AMD eyes, a mixed macrophage infiltrate has been reported,
with both M1 and M2 macrophage populations occurring
(Cao et al., 2011). Similarly, only a subset of macrophages ingeneration in aged VEGF-Ahyper mice (21months old). These round deposits are
ght channel (G), which also shows increased NLRP3 immunostaining at sites of
hite), and CNV lesion formation (CD31, green) occur in VEGF-Ahyper mice,
tative images of choroidal flat mounts from 6-week-old mice are presented.
6 weeks old) in choroidal flat mounts (average CNV lesion numbers/mouse of
in WT control mice. p values were determined with a two-tailed Student’s t test
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Figure 5. Glia Cell Activation in CNV Lesions
in VEGF-Ahyper Mice
(A) In young VEGF-Ahyper mice (6 weeks old), early
RPE degeneration is seen only focally with some
RPE cells undergoing vacuolar degeneration
(intracellular vacuoles with remaining pigment
granules; white arrow). At this stage, retinal
changes are limited, but migration of retinal
Muller glia cells (black arrow) toward sites of
RPE degeneration can already be observed.
Scale bar, 20 mm.
(B) In aged VEGF-Ahyper mice, the photoreceptor
layer adjacent to CNV lesions is present, but
attenuated. Complete loss of photoreceptors is
seen in retina overlying CNV lesions with an
accumulation of retinal Muller glia cells (arrow).
Scale bar, 50 mm. A 21-month-old VEGF-Ahyper
mouse is shown.
(C) At sites of early evolving CNV lesions, sub-
retinal macrophages (F4/80+, white; arrow) are
seen prior to neovessel formation. Limited to
the overlying retina GFAP expression (green)
increases, indicating glia cell activation and
proliferation, whereas adjacent retina appears
unchanged. Scale bar, 50 mm. A 4-month-old
VEGF-Ahyper mouse is shown.
(D) In early CNV lesions with subretinal neo-
vascularization (CD31, red; arrow), GFAP+ glia
cells have increased and have infiltrated early CNV
lesions (green). Scale bar, 50 mm. A 4-month-old
VEGF-Ahyper mouse is shown.
(E) In aged VEGF-Ahyper mice with large CNV
lesions, massive GFAP expression and glia cell
infiltration into sites of CNV lesion formation are
seen (arrow). Scale bar, 50 mm. A 15-month-old
VEGF-Ahyper mouse is shown.
(F) Retinal GFAP is increased in aged VEGF-Ahyper
mice compared to littermate control mice. 16-
month-old mice are shown.
(G) Coimmunolabeling for GFAP (red), IL-1b
(green), and F4/80 (white) shows that high IL-1b
expression is seen in infiltrating retinal glia cells (arrowhead), whereas lower levels are observed in RPE cells and only in a few macrophages in CNV
lesions (arrow). No IL-1b is detected in most choroidal macrophages. Scale bar, 50 mm. A 15-month-old VEGF-Ahyper mouse is shown.
(H) Retinal glia cells coexpress both VEGF-A and IL-1b in the retina overlying CNV lesions where the photoreceptor layer is severely attenuated (arrow). Labeling
for IL-1b and VEGF-A is also seen in RPE cells (arrowhead) in CNV lesions. Scale bar, 50 mm. A 15-month-old VEGF-Ahyper mouse is shown.
(I) Increased VEGF-A expression (green) is seen in retinal glia cells overlying CNV lesions (arrow). Scale bar, 50 mm. A 15-month-old VEGF-Ahyper mouse is shown.
(J) Although IL-1b is expressed in glia cells overlying CNV lesions that have replaced the ONL, adjacent normal-appearing retina (inset) shows only weak IL-1b
expression in the INL (arrow) and GCL (arrowhead). Scale bars, 50 mm. A 15-month-old VEGF-Ahyper mouse is shown.
(K) Infiltrating retinal glia cells show strong expression of IL-18 overlying CNV lesions. Inset shows IL-18 expression in normal retina to be prominent in the INL
(arrowhead). Scale bar, 50 mm. A 15-month-old VEGF-Ahyper mouse is shown.
See also Figure S5.spontaneous CNV lesions in aged VEGF-Ahyper mice was Arg1+
(Figure S6I), reflecting the mixed macrophage populations in
human AMD eyes, which is consistent with a chronic progressive
eye pathology.
Next, mutant mice were generated in which temporal ablation
of macrophages can be induced through injection of diphtheria
toxin (Lysozyme M Cre-iDTR homozygous mice). Selective
temporal ablation ofmacrophages in thesemice inhibited the for-
mation of the SMA+NG2+ myofibroblastic scaffold and glia cell
accumulation in laser lesions and reduced subsequent neovas-
cularization significantly (Figures 6H–6O). Thus, macrophages
promote glia cell activation (with activated glia cells expressing
proangiogenic VEGF-A and IL-1b) and subsequent CNV.954 Cell Reports 4, 945–958, September 12, 2013 ª2013 The AuthorDISCUSSION
The findings in aged VEGF-Ahyper mice reveal that a chronic
increase in VEGF-A levels is sufficient to cause age-dependent
cardinal features of both nonexudative AMD and neovascular
AMD, providing a unifying pathomechanism for advanced
AMD. These features are likely to be a consequence of both
direct as well as indirect effects of increased VEGF-A signaling,
such as through the induction of downstream pathways and
cellular changes. The findings are consistent with the clinical
observation that neovascular AMD can often co-occur with
nonexudative AMD and highlight the notion that AMD can
occur along a spectrum with the manifestations of features ofs
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Figure 6. Macrophages Are Required for Retinal Glia Cell Activation and Subsequent Neovascularization
(A and B) A fibroblast-like scaffold forms after macrophage (red) infiltration that is positive for NG2 (green) and SMA (white). 103 magnification.
(C) The fibroblast-like scaffold forms prior to infiltration of the laser injury site with endothelial cells because the first CD31+ endothelial cells are seen at about 68 hr
after injury, when the NG2+SMA+ scaffold has already formed. 103 magnification.
(D) Neovascularization occurs after macrophage infiltration and after the formation of the SMA+ scaffold, and fully formed CNV lesions are seen at day 5
(CD31, green). The SMA+ scaffold covers the neovascular lesions, resembling a scar after wound injury. 103 magnification. Control mice are shown.
(E) GFAP+ retinal glia cells (arrow) infiltrate the laser injury site already by 72 hr after laser injury, before endothelial cells have populated the site. Scale bar, 50 mm.
(F) At day 4 after laser injury, new blood vessels form at the site of laser injury after GFAP+ cells have already infiltrated the SMA+ scaffold. Scale bar, 50 mm.
Control mice are shown in (A)–(F).
(G) Semiquantitative RT-PCR of choroidal tissue lysates shows an increase of macrophages at 69 hr after laser injury (CD11b levels normalized to 36B4
housekeeping gene), consistent with the immunolabeling results. Macrophage accumulation occurs independently of IL10 or STAT6 signaling (n = 5/group). Error
bars, mean ± SD. **p < 0.01. Ctrl, control.
(H and I) Homozygous LysMCre+iDTR mice were used for DT injections to temporally and selectively ablate myeloid cells in laser injury experiments and
compared to CreiDTR mice. DT treatment potently diminished F4/80+ macrophage infiltration into the laser injury site, assessed here at 68 hr after injury.
Ablation of macrophages also inhibited the SMA+ scaffold formation (I).
(J and K). Ablation of macrophages inhibited GFAP+ glia cell activation (white) and infiltration into the site of laser injury.
(L andM) Inhibition of macrophage infiltration and glia cell activation resulted in a significant inhibition of neovascularization. Only fewCD31+ vessels (green) were
seen at laser injury sites in which macrophage accumulation was reduced, whereas full neovascular lesions formed in mice with no ablation of macrophages.
Scale bars, 50 mm.
(N and O) Reduced CNV lesion formation was seen in mice with selective ablation of macrophages, with a reduction in the total neovascular area and the rate of
CNV lesion formation for each laser injury administered (n = 20 mice/group). Error bars, mean ± SD. *p < 0.05.
See also Figure S6.
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both neovascular and nonexudative forms (Sunness et al.,
1999).
AMD has been proposed to be a multifactorial disease, and
various risk factors for AMD have been identified, including
smoking, advanced age, chronic light exposure, and genetic
risk factors (Friedman et al., 2004; Klein et al., 2004; van Leeu-
wen et al., 2003). The observations of cardinal features of AMD
in aged VEGF-Ahyper mice that only differ from their control litter-
mates by increased VEGF-A levels suggest that in AMD multiple
risk factors may converge to cause mainly RPE hypoxia and
oxidative damage, which stimulate increased VEGF-A expres-
sion in RPE cells (Klettner and Roider, 2009). Thus, although
advanced AMD may result from multifactorial insults to the
RPE in humans, aged VEGF-Ahyper mice serve as a mouse
model for AMD due to a single genetic alteration that leads to
increased VEGF-A levels, demonstrating a central role of
increased VEGF-A signaling in AMD pathogenesis. The observa-
tion in VEGF-Ahyper mice that early RPE degenerative changes
are seen prior to photoreceptor loss provides in vivo evidence
that the RPE is at the center of the disease process in AMD
and that retinal degeneration occurs as a consequence of an
impaired RPE function.
Increased VEGF-A levels are shown here to lead to RPE barrier
breakdown and progressive degenerative changes in the RPE,
which are associated with accumulation of lipid-rich basal
laminar sub-RPE deposits and complement C1q, and an in-
crease in oxidative damage, similarly as in human eyes with
AMD. These RPE abnormalities are linked to NLRP3 inflamma-
some activation, focal RPE cell death, and CNV lesion formation.
Targeting NLRP3 or IL-1b signaling in these mice reduced RPE
barrier breakdown and CNV lesion formation, demonstrating
that the NLRP3 inflammasome contributes to VEGF-A-induced
AMD-like pathologies. IL-18 deficiency had an opposite effect
on CNV lesion formation, suggesting an antiangiogenic effect
of IL-18 (Doyle et al., 2012). Although NLRP3 deficiency
increased the size of laser injury-induced neovascular lesions
in an acute wound-healing model in the eye (Doyle et al.,
2012), an inhibition of CNV lesion number was observed here
in VEGF-Ahyper mice that lack NLRP3. These differences are
not surprising, because in the acute laser injury model, neovas-
cularization occurs in the setting of healthy RPE cells that show
little or no NLRP3 expression, and it occurs within 4 days after
injury. In contrast, CNV lesions in VEGF-Ahyper mice develop
over a prolonged period of time and occur in the setting of
RPE barrier breakdown and VEGF-A associated accumulation
of C1q and oxidative damage, with strong expression of
NLRP3 and inflammasome activation, similar to human AMD.
It is further shown here that RPE barrier breakdown leads to
accumulation of macrophages into the space between the RPE
and the retina, with subsequent activation of retinal Muller glia
cells that strongly express the proangiogenic factors IL-1b and
VEGF-A to promote CNV. These findings are consistent with
observations that showed human neovascular AMD lesions to
contain a large number of IL-1b-expressing cells and RPE cells
to express VEGF-A (Oh et al., 1999).
In summary, aged VEGF-Ahyper mice serve as an important
new mouse model for both forms of AMD and reveal a central
role of increased VEGF-A and NLRP3 inflammasome activation956 Cell Reports 4, 945–958, September 12, 2013 ª2013 The Authorfor RPE degeneration and AMD pathogenesis. Preventative
strategies to reduce RPE hypoxia or therapeutically target
increased VEGF-A signaling in combination with blocking IL-1b
or the NLRP3 inflammasome could therefore inhibit both forms
of AMD.
EXPERIMENTAL PROCEDURES
Animals
The generation of VEGF-Ahyper mice and VEGF-Ahypo mice was previously re-
ported by Miquerol et al. (1999) and Damert et al. (2002). VEGF-Ahyper mice
were crossed with IL-18/, IL-1R1/, or NLRP3/ mice to obtain mice
that are heterozygous for the VEGF-Ahyper allele and homozygous null for
IL-18, IL-1R1, or NLRP3 (Jackson Laboratory) (Takeda et al., 1998; Glaccum
et al., 1997; Brydges et al., 2009).
Immunolabeling
Eyes were fixed in 4% paraformaldehyde. For choroidal flat mounts, eyes
were permeabilized in 0.5% Triton X-100 and subsequently blocked with
5% serum in which the secondary antibodies were raised. A full description
of antibodies used is provided in the Extended Experimental Procedures.
Staining for b-gal activity was performed as described previously (Marneros
et al., 2005).
Western Blotting
Eye tissues from VEGF-Ahyper mice and control littermate mice of different
ages were used for western blotting experiments. Freshly dissected posterior
eye poles were lysed in NP40 lysis buffer with 1 mM PMSF and protease inhib-
itor cocktail using the QIAGEN TissueLyser II. After centrifugation, the super-
natant was used for western blotting. A full description of antibodies used is
provided in Extended Experimental Procedures.
Experimental CNV Model
Eyes of age- and gender-matched mice were exposed to laser photocoagula-
tion for induction of experimental CNV after eyes were dilated with 1% tropi-
camide and mice were anesthetized with 75 mg/kg ketamine and 7.5 mg/kg
xylazine. Laser photocoagulation was performed using a 532 nm laser (Zeiss;
VISULAS 532s). Lesions were induced using a power of 200mW, a spot size of
50 mm, and a duration of 100 ms as previously described (He and Marneros,
2013).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and one table and can be found with this article online at http://dx.
doi.org/10.1016/j.celrep.2013.08.002.
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